Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens

Completed · Not applicable

Conditions studied: Cataract

In brief

The objective of the study is to evaluate the safety and effectiveness of the enVista trifocal intraocular lens when implanted in the capsular bag.

Key facts

Study ID

NCT03603600

Run by

Bausch & Lomb Incorporated

People needed

501

Starts

2018-05-31

Expected to finish

2023-05-04

Last updated by the study team

2024-12-24

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects must be 22 years of age or older on the date the Informed Consent Form (ICF) is signed.
• Subjects must have the capability to understand and provide written informed consent on the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved Informed Consent Form (ICF) and authorization as appropriate for local privacy regulations.
• Subjects must have a BCDVA equal to or worse than 20/40 in each eye, with or without a glare source, due to a clinically significant cataract (cortical, nuclear, subcapsular, or combination) that is considered amenable to treatment with standard phacoemulsification cataract extraction and capsular IOL implantation.
• Subjects must have a BCDVA projected to be better than 20/32 after IOL implantation in each eye, as determined by the medical judgment of the Investigator or measured by potential acuity meter (PAM) testing, if necessary.
• Subjects must have clear intraocular media other than the cataract in both eyes.
• Contact lens wearers must demonstrate a stable refraction (within ±0.50 D for both sphere and cylinder) in both eyes, as determined by distance manifest refraction on two consecutive examination dates after discontinuation of contact lens wear.
• Subjects must require an IOL power from +16.0 diopter (D) to +24.0 D in both eyes.
• Subjects must be willing and able to comply with all treatment and follow-up study visits and procedures, and to undergo second eye surgery within 7-30 days of the first eye surgery.

You may not qualify if…

• Subjects who have used an investigational drug or device within 30 days prior to entry into this study and/or will participate in another investigation during the period of study participation.
• Subjects who have any corneal pathology (e.g., significant scarring, guttata, inflammation, edema, dystrophy, etc.) in either eye.
• Subjects who have significant anterior segment pathology that might increase intraoperative risk or compromise IOL stability (e.g., pseudoexfoliation syndrome, synechiae, iris atrophy, traumatic cataract, lens subluxation, traumatic zonulolysis, zonular dialysis, evident zonular weakness or dehiscence, hypermature or brunescent cataract, etc.) in either eye.
• Subjects who have uncontrolled glaucoma in either eye.
• Subjects who have previous retinal detachment or clinically significant retinal pathology involving the macula in either eye.
• Subjects who have proliferative or non-proliferative diabetic retinopathy in either eye.
• Subjects who have a congenital ocular anomaly (e.g., aniridia, congenital cataract) in either eye.
• Subjects using any systemic or topical drug known to interfere with visual performance, pupil dilation, or iris structure within 30 days of enrollment or during the study (refer to the relevant attachment of the Study Reference Manual).
• Subjects who have a history of chronic or recurrent inflammatory eye disease (e.g., iritis, scleritis, iridocyclitis, or rubeosis iridis) in either eye.
• Subjects who have a visual disorder, other than cataracts, that could potentially cause future acuity losses to a level of 20/100 or worse in either eye.
• Subjects who have had previous intraocular or corneal surgery in either eye, with the exception of laser trabeculoplasty.
• Subjects with any preoperative infectious conjunctivitis, keratitis, or uveitis in either eye.
• Subjects who have a preoperative corneal astigmatism > 1.0 D in either eye, irregular astigmatism, or skewed radial axis (note: corneal incisions intended specifically to reduce astigmatism are not allowed during the study).
• Subjects who cannot achieve a minimum pharmacologic pupil dilation of 5.0 mm in both eyes.
• Subjects who may be expected to require a combined or other secondary surgical procedure in either eye.
• Subjects who during the first cataract extraction experience an anterior or posterior capsule tear or rupture, zonular dialysis, significant iris trauma, or other complication that may cause untoward effects in the judgment of the Investigator.
• Females of childbearing potential (those who are not surgically sterilized or at least 12 months postmenopausal) are excluded from enrollment in the study if they are currently pregnant or plan to become pregnant during the study. Females of childbearing potential must be willing to practice effective contraception for the duration of the study.
• Subjects with any other serious ocular pathology or underlying systemic medical condition (e.g., uncontrolled diabetes) or circumstance that, based on the Investigator's judgment, poses a concern for the subjects' safety or could confound the results of the study.
• Subjects who have current or previous usage of an alpha-1-selective adrenoceptor blocking agent or an antagonist of alpha 1A adrenoceptor (e.g., Flomax® (tamsulosin HCl), Terazosin, or Cardura).

Where it is running

• Bausch Site 108 — Fayetteville, Arkansas, United States
• Bausch Site 113 — Garden Grove, California, United States
• Bausch Site 120 — Northridge, California, United States
• Bausch Site 115 — Redding, California, United States
• Bausch Site 103 — Torrance, California, United States
• Bausch Site 107 — Mt. Dora, Florida, United States
• Bausch Site 117 — Lake Villa, Illinois, United States
• Bausch Site 101 — Bloomington, Minnesota, United States
• Bausch Site 119 — Birmingham, Mississippi, United States
• Bausch Site 102 — St Louis, Missouri, United States
• Bausch Site 124 — Omaha, Nebraska, United States
• Bausch Site 118 — Las Vegas, Nevada, United States
• Bausch Site 106 — Brecksville, Ohio, United States
• Bausch Site 109 — Columbus, Ohio, United States
• Bausch Site 116 — Pittsburgh, Pennsylvania, United States
• Bausch Site 121 — Sioux Falls, South Dakota, United States
• Bausch Site 112 — Memphis, Tennessee, United States
• Bausch Site 110 — Nashville, Tennessee, United States
• Bausch Site 104 — Cedar Park, Texas, United States
• Bausch Site 105 — Dallas, Texas, United States
• Bausch Site 111 — Houston, Texas, United States
• Bausch Site 122 — San Antonio, Texas, United States
• Bausch Site 123 — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.